摘要
Abstract
Objective To observe the effect of recombinant human urokinase on acute ST segment elevation myocar-dial infarction(STEMI) and its effect on the serum C reactive protein and complement C3.Methods From June 2013 to June 2015, 90 patients with STEMI were randomly divided into the control group and the observation group with 45 cases of patients in each group in the Central Hospital of Karamay Xinjiang Autonomous Region, The control group was treated with routine treatment, and the observation group was treated with recombinant human urokinase on the basis of conventional treatment.Af-ter treatment, the patients’ vascular recanalization at different time, before and after treatment lipid levels, and ET-1, NO and hs CRP and C3 levels and cardiovascular events occurred, adverse reactions were compared and analyzed in the two groups.Results After the treatment of 60 min, 90 min and 120 min in the observation group, the recanalization rate was sig-nificantly higher than that of the control group( P<0 .05).Compared with before treatment, 2 groups of patients’ TC, TG, LDL-C, ET-1 and NO were significantly improved, and the observation group improved significantly better than the control group( P <0.05, P <0.01).Two groups of patients’ hs CRP and C3 levels were significantly improved compared to before treatment (P <0.05), and observation group improved significantly better than the control group ( P <0.05).The observa-tion group’ s incidence of myocardial infarction, angina pectoris, arrhythmia were significantly lower than those of the control group ( P <0.05), and the occurrence of heart failure rate and mortality rate showed no significant difference with the control group ( P >0.05).Observation group’s liver function abnormalities, myalgia’s incidence rate was 0, 8.88%, which was significantly lower than that in the control group of 11.11%and 22.22%( P <0.05);2 group patients’ fatigue, digestive tract reaction incidence showed no statistically significant difference ( P >0.05).Conclusion Recombinant human uroki-nase in the treatment of STEMI patients can improve the patency rate of coronary artery and optimize the lipid level.关键词
重组人尿激酶/急性ST段抬高型心肌梗死/溶栓治疗Key words
Recombinant human urokinase/Acute ST segment elevation myocardial infarction/Thrombolytic therapy
